You are about to leave the Clinical Value website now.


Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis

Quick Summary

The recently published Chinese standards for the diagnosis and treatment of primary liver cancer [1] mention various screening strategies, including abdominal ultrasonography (US), serological tests such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II).

However, combined screening strategies may be associated with increased costs. The Chinese guidelines [2] highlight that there is a lack of health economic evaluations and evidence on the cost–effectiveness of different liver cancer screening strategies.

This study aims to compare the cost-effectiveness of seven screening strategies:

  1. US
  2. AFP
  4. AFP+US
  6. GAAD
  7. GAAD+US

This was done by developing a health economic model from the Chinese healthcare system perspective to identify the most cost-effective strategy for early detection of liver cancer in patients with chronic hepatitis B in China.


  1. General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 Edition). Infect. Dis. Info. 35(1), 1–26 (2022).
  2. He J, Chen W, Shen H et al. China guideline for liver cancer screening (2022, Beijing). J. Clin. Hepatol. 38(8), 1739–1758 (2022).

You May Also Like

Navigating the Health Economic Data in APAC: Present challenges and future directions

Read More
14 March 2023

Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions

This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in…

Read More
18 September 2023

Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective

In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem, some of the challenges…

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.